Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT02277639 Completed - Immunodeficiencies Clinical Trials

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

MiniClini
Start date: November 2011
Phase: Phase 2
Study type: Interventional

This is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from mismatched donors. There are two conditioning regimens depending upon patient diagnosis and age.

NCT ID: NCT02276105 Completed - Clinical trials for Carpal Tunnel Syndrome

Investigation of Psychometric Properties of the EuroQoL EQ-5D-5L in Patients With Carpal Tunnel Syndrome

Start date: October 2014
Phase: N/A
Study type: Observational

The purpose of this study is to determine how appropriate and practically is the EQ-5D questionnaire in use on patients with carpal tunnel syndrome undergoing surgery along the change of quality of life.

NCT ID: NCT02273791 Completed - Infertility Clinical Trials

HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients

Start date: December 2013
Phase:
Study type: Observational

Evaluation of endometrial preparation using either hormonal therapy or ovarian stimulation prior to frozen-thawed embryo transfer (FET) in patients with polycystic ovarian syndrome (PCOS)

NCT ID: NCT02273245 Completed - Clinical trials for Acute Aortic Syndrome

Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?

Start date: January 2015
Phase: N/A
Study type: Observational

Acute Aortic Syndrome (AAS) is a potentially life-threatening cause of sudden, severe chest pain. There are several possible underlying causes, which cannot be distinguished from one another at the bedside. Current practice is to image this with two CT scans of the chest, one before injection of a contrast dye into the blood stream and then one after. With the advancement of CT scanner technology, improvements in software interpretation and screen resolution, the investigators hypothesise that performing the contrast scan on its own is diagnostically equivalent to both the pre- and contrast scans

NCT ID: NCT02273102 Completed - Leukemia Clinical Trials

Study of TCP-ATRA for Adult Patients With AML and MDS

TCP-ATRA
Start date: March 2, 2015
Phase: Phase 1
Study type: Interventional

Acute Myeloid Leukemia (AML) is a diverse disease that is fatal in the majority of patients. Acute promyelocytic leukemia (APL) however, a subtype of AML accounting for 5% of all cases, is very curable. APL cells are highly sensitive to the retinoid all-trans-retinoic acid (ATRA), which effectively differentiates the leukemic clone. Over 80% of APL patients can be cured with ATRA based therapies. For patients with non-APL AML, ATRA has little effect. Consequently, 85% of these patients will succumb to their disease despite conventional approaches. Little is known about mechanisms of resistance to ATRA in non-APL AML. This knowledge gap limits the use of ATRA in a disease that already has few effective therapies. The investigators' preliminary data suggest that non-APL AML cells can be re-sensitized to ATRA when combined with lysine-specific demethylase 1 (LSD 1) inhibitors. The investigators' publication in Nature Medicine showed that LSD1 inhibition with tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. Notably, treatment with ATRA and TCP markedly diminished the engraftment of primary human AML cells in murine models, indicating that the combination may target leukemia-initiating cells (LIC). The investigators' data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to ATRA resistance in non-APL AML. The investigators' central hypothesis is that ATRA combined with TCP will be safe and effective in a clinical population, and that this approach will suppress LICs and restore myeloid differentiation programs in patients with non-APL AML. Testing this hypothesis with the phase I clinical trial outlined in this protocol, will establish a new treatment paradigm in AML and extend the important anti-cancer effects of ATRA to all AML subtypes.

NCT ID: NCT02270268 Completed - Clinical trials for Irritable Bowel Syndrome

Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome

Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effect of pectin, a kind of soluble dietary fiber, on clinical symptoms, gut microbiota and the immune status in patients with diarrhea-predominant irritable bowel syndrome

NCT ID: NCT02268383 Completed - Clinical trials for Myelodysplastic Syndromes

ACE-536 Extension Study - Myelodysplastic Syndromes

Start date: October 2014
Phase: Phase 2
Study type: Interventional

Study A536-05 is an open-label extension study for patients previously enrolled in study A536-03 (ClinicalTrials.gov Identifier NCT01749514), to evaluate the long-term safety and tolerability of ACE-536 in patients with low or intermediate-1 risk MDS.

NCT ID: NCT02265068 Completed - Clinical trials for Acute Coronary Syndrome (ACS)

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Real-TICA
Start date: August 2014
Phase:
Study type: Observational

Documentation of long-term data regarding ticagrelor use and evaluation of reasons for discontinuation of ticagrelor in patients with ACS

NCT ID: NCT02263781 Not yet recruiting - Obesity Clinical Trials

PREPL in Health and Disease

PHD
Start date: October 2014
Phase: N/A
Study type: Interventional

Evaluation of PREPL activity in healthy controls and known or possible PREPL deficient patients

NCT ID: NCT02262312 Completed - Clinical trials for Myelodysplastic Syndrome

Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome

Start date: September 2014
Phase: Phase 0
Study type: Observational

Patients with myelodysplastic syndrome (MDS) have an ineffective hemopoiesis and often suffer from anemia. This can lead to red blood cell transfusion dependency and iron overload. Iron overload can affect the liver and lead to liver fibrosis and worst case cirrhosis. Ferritin is usually used to monitor the iron overload. In this study MDS patients will have a transient elastography performed which measures the liver's stiffness. The purpose is to investigate whether liver stiffness measurements are coherent to ferritin levels.